{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:49:04Z","timestamp":1794718144643,"version":"4.9.1"},"reference-count":14,"publisher":"Consortium of Multiple Sclerosis Centers","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1,1]]},"abstract":"<jats:p>This phenomenological investigation was undertaken to gain a better understanding of multiple sclerosis (MS) patients' experience with natalizumab (Tysabri; Biogen Idec Inc, Cambridge, MA) treatment and its impact on their quality of life (QOL). Twenty MS patients who were receiving natalizumab treatment were recruited by the physicians, nurse practitioners, nurses, and social worker of the William C. Baird Multiple Sclerosis Center in Buffalo, New York, between March 2009 and November 2009. Patients were invited to participate if they had relapsing-remitting MS, had received at least six treatments of natalizumab, and could articulate their experience. An interviewer obtained informed consent, gathered basic demographic information, and then tape-recorded the participants' accounts of their experience with natalizumab. The audio-recorded interviews were transcribed and de-identified before being submitted to the investigators for analysis. The Atlas.ti qualitative data analysis program (Scolari, Berlin, Germany) was used to manage the data. Patients found natalizumab easy to tolerate and effective; moreover, they described improvement in their QOL. Patients must weigh the benefits of control of their MS against the increased risk of developing progressive multifocal leukoencephalopathy with natalizumab treatment. Information from this study will be used to educate professionals involved in MS patient care as well as patients and families considering treatment with natalizumab.<\/jats:p>","DOI":"10.7224\/1537-2073-14.1.39","type":"journal-article","created":{"date-parts":[[2012,4,5]],"date-time":"2012-04-05T13:46:06Z","timestamp":1333633566000},"page":"39-44","source":"Crossref","is-referenced-by-count":16,"title":["Relapsing-Remitting Multiple Sclerosis Patients' Experience with Natalizumab"],"prefix":"10.7224","volume":"14","author":[{"given":"Colleen E.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Karpinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Jezewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4242","reference":[{"key":"2020071713454597400_i1537-2073-14-1-39-b1","article-title":"Programme on mental health. WHO-QOL: measuring quality of life","author":"World Health Organization"},{"key":"2020071713454597400_i1537-2073-14-1-39-b2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1477-7525-7-68","article-title":"The impact of regular physical activity on fatigue, depression, and quality of life in persons with multiple sclerosis","volume":"7","author":"Stroud","year":"2009","journal-title":"Health Qual Life Outcomes."},{"key":"2020071713454597400_i1537-2073-14-1-39-b3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1348\/014466508X379566","article-title":"Attentional lapses, emotional regulation and quality of life in multiple sclerosis","volume":"48","author":"Phillips","year":"2009","journal-title":"Br J Clin Psychol."},{"key":"2020071713454597400_i1537-2073-14-1-39-b4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ana.21163","article-title":"Health-related quality of life in multiple sclerosis: effects of natalizumab","volume":"62","author":"Rudick","year":"2007","journal-title":"Ann Neurol."},{"key":"2020071713454597400_i1537-2073-14-1-39-b5","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/01376517-199710000-00003","article-title":"The lived experience of relapsing multiple sclerosis: a phenomenological study","volume":"29","author":"Miller","year":"1997","journal-title":"J Neurosci Nurs."},{"key":"2020071713454597400_i1537-2073-14-1-39-b6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/01376517-200110000-00004","article-title":"A phenomenological assessment of relapsing MS patients' experiences during treatment with interferon beta-1a","volume":"33","author":"Miller","year":"2001","journal-title":"J Neurosci Nurs."},{"key":"2020071713454597400_i1537-2073-14-1-39-b7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/01376517-200602000-00008","article-title":"Relapsing MS patients' experiences with glatiramer acetate treatment: a phenomenological study","volume":"38","author":"Miller","year":"2006","journal-title":"J Neurosci Nurs."},{"key":"2020071713454597400_i1537-2073-14-1-39-b8","first-page":"31","article-title":"A historical overview of the phenomenological movement","volume":"19","author":"Cohen","year":"1987","journal-title":"Image."},{"key":"2020071713454597400_i1537-2073-14-1-39-b9","unstructured":"Heidegger\n              M.\n            \n          \n          Being and Time. MacqarreJ, RobinsonE, trans. 1962. New York, NY: Harper and Row; 1962."},{"key":"2020071713454597400_i1537-2073-14-1-39-b10","unstructured":"Kockelmans\n              JJ.\n            \n          \n          Heidegger's \u201cBeing and Time\u201d: The Analytic of Dasein as Fundamental Ontology. Washington, DC: Center for Advanced Research in Phenomenology, University Press of America; 1989."},{"key":"2020071713454597400_i1537-2073-14-1-39-b11","first-page":"48","article-title":"Psychological research as the phenomenologist views it","author":"Colaizzi","year":"1978","journal-title":"Existential Phenomenological Alternatives for Psychology"},{"key":"2020071713454597400_i1537-2073-14-1-39-b12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1891\/0739-6686.17.1.269","article-title":"Uncertainty in chronic illness","volume":"17","author":"Mishel","year":"1999","journal-title":"Annu Rev Nurs Res."},{"key":"2020071713454597400_i1537-2073-14-1-39-b13","unstructured":"Charmaz\n              K.\n            \n          \n          Good Days, Bad Days: The Self in Chronic Illness and Time. New York, NY: McGraw Hill; 1991."},{"key":"2020071713454597400_i1537-2073-14-1-39-b14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JNN.0b013e31820297a9","article-title":"Emerging oral therapies for multiple sclerosis","volume":"43","author":"Miller","year":"2011","journal-title":"J Neurosci Nurs."}],"container-title":["International Journal of MS Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/14\/1\/39\/2553782\/1537-2073-14_1_39.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/14\/1\/39\/2553782\/1537-2073-14_1_39.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:11:37Z","timestamp":1752786697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijmsc.org\/view\/relapsing-remitting-multiple-sclerosis-patients-experience-with-natalizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1,1]]}},"URL":"https:\/\/doi.org\/10.7224\/1537-2073-14.1.39","relation":{},"ISSN":["1537-2073"],"issn-type":[{"value":"1537-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1,1]]}}}